Clay B. Siegall, Ph.D. is a pioneer in modern cancer treatment. Dr. Siegall, co-founder of Seattle Genetics has overseen the company in its recent development of antibody-drug conjugates (ADCs). This has led to the 2011 approval of ADCETRIS, produced by Takeda Pharmaceutical Company. These developments are critical to the much-needed development of targeted drugs to better help cancer patients. Several companies have joined in with Seattle Genetics. Overall the company has received over 1.2 billion in private and public funding. The project has also generated over 350 million with collaborators and the drug is approved for use in over 65 countries.
Dr. Clay Siegall is a graduate of the University of Maryland, with a B.S. in Zoology, and also holds a Ph.D. in Genetics from George Washington University. His experience includes working with Bristol-Myers Squibb in their Pharmaceutical Research Institute and has also worked with the National Cancer Institute. His passion for wanting to help find a cure to cancer came from seeing the struggle his father had until he passed when Siegall was only 24 years old. Dr. Siegall also sits on the board of directors of other pharmaceutical companies and is often included in think tanks and round-table efforts.
Dr. Siegall has earned many awards over the years. His alma mater declared him alumni of the year and he’s also been deemed an entrepreneur of the year. He’s published over 70 scholarly and research related works and has 15 patents. Siegall knows and understands the challenge oncology doctors face when they treat patients. As mentioned regularly in the news, there simply isn’t enough information at their disposal. Collaborating with other efforts to expand the data being made available to doctors for the (same) purpose of finding targeted treatments will hopefully bring us closer to a united goal of ending cancer permanently.